Larimar Therapeutics, Inc. (LRMR)
3.85
-0.02
(-0.52%)
USD |
NASDAQ |
Sep 03, 11:25
Larimar Therapeutics Shareholders Equity (Quarterly) : 127.38M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 127.38M |
| March 31, 2026 | 158.03M |
| December 31, 2025 | 78.08M |
| September 30, 2025 | 139.04M |
| June 30, 2025 | 119.85M |
| March 31, 2025 | 144.27M |
| December 31, 2024 | 171.81M |
| September 30, 2024 | 198.40M |
| June 30, 2024 | 211.40M |
| March 31, 2024 | 230.84M |
| December 31, 2023 | 81.72M |
| September 30, 2023 | 92.71M |
| June 30, 2023 | 99.93M |
| March 31, 2023 | 106.24M |
| December 31, 2022 | 110.90M |
| September 30, 2022 | 118.66M |
| June 30, 2022 | 50.06M |
| March 31, 2022 | 57.10M |
| December 31, 2021 | 64.41M |
| September 30, 2021 | 72.07M |
| June 30, 2021 | 67.52M |
| March 31, 2021 | 78.78M |
| December 31, 2020 | 89.69M |
| September 30, 2020 | 102.64M |
| June 30, 2020 | 112.54M |
| Date | Value |
|---|---|
| March 31, 2020 | 50.74M |
| December 31, 2019 | -0.694M |
| September 30, 2019 | 59.88M |
| June 30, 2019 | 72.14M |
| March 31, 2019 | 82.36M |
| December 31, 2018 | 93.27M |
| September 30, 2018 | 103.94M |
| June 30, 2018 | 52.02M |
| March 31, 2018 | 65.00M |
| December 31, 2017 | 78.22M |
| September 30, 2017 | 89.23M |
| June 30, 2017 | 99.63M |
| March 31, 2017 | 110.77M |
| December 31, 2016 | 121.73M |
| September 30, 2016 | 130.17M |
| June 30, 2016 | 142.24M |
| March 31, 2016 | 154.43M |
| December 31, 2015 | 169.11M |
| September 30, 2015 | 189.70M |
| June 30, 2015 | 206.19M |
| March 31, 2015 | 221.67M |
| December 31, 2014 | 104.44M |
| September 30, 2014 | 111.20M |
| June 30, 2014 | 125.42M |
| March 31, 2014 | 31.38M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| SELLAS Life Sciences Group, Inc. | 137.66M |
| Marker Therapeutics, Inc. | 12.17M |
| Rezolute, Inc. | 116.83M |
| Krystal Biotech, Inc. | 1.359B |
| ACADIA Pharmaceuticals, Inc. | 1.307B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 165.30M |
| Total Liabilities (Quarterly) | 37.92M |
| Debt to Equity Ratio | 0.0389 |
| Current Ratio | 4.703 |
| Net Debt Paydown Yield | -0.01% |